...

From Soil Sample to Nobel Prize: The Story of Ivermectin

Flat teal illustration of a sprouting plant in soil, a microscope and a tablet for an article on the history of ivermectin

Most medicines trace back to a laboratory bench or a pharmaceutical pipeline. Ivermectin has a more unusual beginning. Its roots lie in a handful of soil collected in Japan, a microbe nobody had described before, and a partnership between a university-trained microbiologist and an industry parasitologist. Understanding that history helps explain why the medicine is still discussed so widely today.

This article follows the story from the soil to the clinic. It is a history lesson, not treatment advice. Ivermectin is a prescription medicine, and the right decision about whether to use it, and at what dose, belongs to a doctor who knows your situation.

Along the way we will look at how the discovery was recognised, how it reached some of the world’s poorest communities, and what the story teaches patients who are prescribed it today.

Where ivermectin fits today

To appreciate the history, it helps to know where the medicine ended up. Public health agencies describe ivermectin as the recommended treatment for river blindness, a disease spread by blackflies near fast-flowing rivers. According to the CDC guidance on onchocerciasis treatment, ivermectin is given as a long-term course, repeated about every six months for as long as the adult worms might live or while symptoms persist.

Beyond river blindness, doctors may prescribe it for other parasitic conditions, depending on the country and the approved labeling. Examples include strongyloidiasis and certain mite infestations. The official prescribing information sets out the approved uses in plain terms and is worth reading alongside any advice from your doctor.

A microbe in a soil sample

In the 1970s, the Japanese microbiologist Satoshi Ōmura was studying soil bacteria at the Kitasato Institute, looking for natural compounds with medical potential. He collected soil from different places, including a sample taken near a golf course, and grew the organisms he found in the laboratory. One of them turned out to be a previously unknown bacterium that was later named Streptomyces avermitilis.

Ōmura’s team cultured these bacteria and shared promising samples with the pharmaceutical company Merck. There, the parasitologist William Campbell and his colleagues tested the cultures against parasites in animals. One culture stood out. It strongly reduced worm burdens in test animals, and the active compounds were named avermectins.

From avermectin to ivermectin

The natural avermectins were promising but not perfect. Chemists made a small modification to one of them, and the result was ivermectin, a compound with a favorable balance of activity and tolerability in animals. It was first sold for veterinary use in the early 1980s, and it quickly became a widely used animal medicine.

The key finding for human health came next. Because the parasites that cause river blindness are close relatives of worms that infect animals, researchers asked whether the same compound could help people. Clinical studies followed, and human use began in the late 1980s, starting with river blindness.

How the medicine is thought to work

Ivermectin binds to specific channels on the nerve and muscle cells of certain parasites. This disrupts how those cells work, which leads to paralysis and death of the parasite. Human cells carry far fewer of these channels in the places the medicine normally reaches, which is part of why the drug is generally well tolerated when used as directed.

  • It targets larvae well. In river blindness, ivermectin mainly clears the tiny immature worms, known as microfilariae, rather than the adult worms.
  • It needs repeating. Because adult worms survive, treatment is repeated at intervals instead of being a single cure.
  • It does not work on everything. Some parasites, including many tapeworms and flukes, are not affected in the same way.

A shared Nobel Prize

In 2015, Ōmura and Campbell shared half of the Nobel Prize in Physiology or Medicine for their work on avermectin. The other half went to Tu Youyou for her discoveries concerning artemisinin, a malaria treatment. The prize highlighted a theme that links both stories: natural products, studied carefully, can lead to treatments for diseases that affect millions of people.

Recognition of this kind does not change how an individual patient should use the medicine. A Nobel Prize speaks to the importance of the discovery, not to whether ivermectin is right for any particular person or condition.

Reaching the people who needed it

River blindness mostly affects communities in remote rural areas with limited access to health care. In 1987, Merck announced that it would donate ivermectin for river blindness for as long as it was needed. That decision became the basis of a long-running donation program, and it allowed national health programs and partners to organise community treatment.

The same approach later supported programs against lymphatic filariasis, where ivermectin is used in combination with other medicines in some regions. These programs work because treatment is supervised, repeated and matched to local conditions, not because the tablet is casually available.

Lessons from community programs

Mass treatment programs also taught doctors important safety lessons. In parts of central Africa, people infected with another worm, Loa loa, can develop serious reactions after ivermectin, which is why programs adapted their approach and why loiasis screening matters in some settings. Some people with river blindness also feel itchy or feverish after a first dose, a response described in our article on the Mazzotti reaction.

What the history means for patients today

The story of ivermectin is a reminder that a medicine’s usefulness depends on matching it to the right condition, the right person and the right dose. A few practical points follow from that.

  • Get a diagnosis first. Itchy skin could be eczema, an allergy or scabies, and each needs different care.
  • Dosing is individual. Doses of oral ivermectin are usually based on body weight and the condition being treated, so they should come from a prescriber, not from guesswork or from products made for animals.
  • Tell your doctor everything you take. Other medicines, supplements and alcohol can matter, as explained in our guide to drug interactions.
  • Do not use it for COVID-19. Ivermectin is not an approved treatment or preventive for COVID-19, and health authorities advise against using it for that purpose.

Safety reminders

Ivermectin is a prescription medicine and should be used only as directed by a doctor. Common side effects reported in the labeling include dizziness, nausea, diarrhea and itching, and some reactions relate to the parasite dying off rather than to the medicine itself. Seek medical advice promptly for a severe rash, swelling of the face, vision changes, confusion or any symptom that worries you.

Evidence is still developing for some uses discussed in the media and online. Where studies are limited or results are mixed, doctors tend to rely on approved indications and official guidance, and patients should do the same.

Frequently asked questions

Who discovered ivermectin?

The work is credited to Satoshi Ōmura, who isolated the soil bacterium, and William Campbell, who led the testing of its compounds at Merck. They shared a Nobel Prize in 2015 for their work on avermectin.

Was ivermectin first a human medicine?

No. It was developed first as an animal medicine in the early 1980s. Human use followed later in the decade, beginning with river blindness.

Is ivermectin for humans the same as the products used for animals?

Not in a way that makes them interchangeable. Human medicines are made, dosed and labeled for people. Products made for animals contain different strengths and ingredients and can be harmful if taken by a person.

Can I take ivermectin without a prescription?

Oral ivermectin is a prescription medicine in most countries. A doctor needs to confirm the diagnosis, choose the dose and check for risks before it is used.

Where can I read about approved uses and warnings?

The official labeling in your country is the most reliable starting point, and your doctor or pharmacist can explain it in the context of your own health.

This article is for general information only and is not a substitute for professional medical advice, diagnosis or treatment. Always speak to a qualified doctor or pharmacist before starting, changing or stopping any medicine.

November 18, 2026 Dr. Edward Beyer

Seraphinite AcceleratorOptimized by Seraphinite Accelerator
Turns on site high speed to be attractive for people and search engines.